MicroRNA‑302a inhibits cell proliferation and invasion, and induces cell apoptosis in hepatocellular carcinoma by directly targeting VEGFA

Qin,Chenglin; Zha,Wenzhang; Fan,Rengen; Ding,Huimin; Xu,Yonghua; Wang,Chen

doi:10.3892/mmr.2017.7312

MicroRNA‑302a inhibits cell proliferation and invasion, and induces cell apoptosis in hepatocellular carcinoma by directly targeting VEGFA

Authors:
- Chenglin Qin
- Wenzhang Zha
- Rengen Fan
- Huimin Ding
- Yonghua Xu
- Chen Wang
View Affiliations

Affiliations: Department of General Surgery, The Fourth Affiliated Hospital of Nantong Medical College, Yancheng City No. 1 People's Hospital, Yancheng, Jiangsu 224001, P.R. China
Published online on: August 22, 2017 https://doi.org/10.3892/mmr.2017.7312
Pages: 6360-6367

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer‑related mortality worldwide. An increasing number of studies have demonstrated that microRNAs may be used as diagnostic, therapeutic and prognostic targets for human cancers, including HCC. The present study aimed to evaluate microRNA (miR)‑302a expression and function in HCC, and its underlying mechanisms. The results revealed that miR‑302a was expressed at low levels in HCC tissues and cell lines. Reduced miR‑302a expression was correlated with tumor‑node‑metastasis stage and lymph node metastasis in patients with HCC. Additionally, overexpression of miR‑302a reduced cell proliferation and invasion, and induced apoptosis in HCC cells. Vascular endothelial growth factor A (VEGFA) was demonstrated to be a direct target gene of miR‑302a. VEGFA was highly expressed in HCC tissues and inversely correlated with miR‑302a expression. Knockdown of VEGFA expression led to reduced HCC cell proliferation and invasion, and increased apoptosis rates, similar to miR‑302a overexpression, which suggested that VEGFA may be a functional downstream target of miR‑302a in HCC. These data suggested that this newly identified miR‑302a/VEGFA axis may be involved in HCC formation and progression. The present results also provide novel potential targets for the treatments of patients with HCC.

View Figures

View References

1	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
3	Dhanasekaran R, Limaye A and Cabrera R: Hepatocellular carcinoma: Current trends in worldwide epidemiology, risk factors, diagnosism, and therapeutics. Hepat Med. 4:19–37. 2012.PubMed/NCBI
4	Xu L, Zhang M, Zheng X, Yi P, Lan C and Xu M: The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma. J Cancer Res Clin Oncol. 143:17–27. 2017. View Article : Google Scholar : PubMed/NCBI
5	Hou B, Jian Z, Chen S, Ou Y, Li S and Ou J: Expression of miR-216a in pancreatic cancer and its clinical significance. Nan Fang Yi Ke Da Xue Xue Bao. 32:1628–1631. 2012.(In Chinese). PubMed/NCBI
6	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
7	Krol J, Loedige I and Filipowicz W: The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 11:597–610. 2010.PubMed/NCBI
8	Choi E, Choi E and Hwang KC: MicroRNAs as novel regulators of stem cell fate. World J Stem Cells. 5:172–187. 2013. View Article : Google Scholar : PubMed/NCBI
9	Zhou W, Zou B, Liu L, Cui K, Gao J, Yuan S and Cong N: MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4. Oncotarget. 7:74059–74073. 2016.PubMed/NCBI
10	Wang CY, Zhang JJ, Hua L, Yao KH, Chen JT and Ren XQ: MicroRNA-98 suppresses cell proliferation, migration and invasion by targeting collagen triple helix repeat containing 1 in hepatocellular carcinoma. Mol Med Rep. 13:2639–2644. 2016. View Article : Google Scholar : PubMed/NCBI
11	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M and Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004; View Article : Google Scholar : PubMed/NCBI
12	Liu S, Liu K, Zhang W, Wang Y, Jin Z, Jia B and Liu Y: miR-449a inhibits proliferation and invasion by regulating ADAM10 in hepatocellular carcinoma. Am J Transl Res. 8:2609–2619. 2016.PubMed/NCBI
13	Wang LL, Wang L, Wang XY, Shang D, Yin SJ, Sun LL and Ji HB: MicroRNA-218 inhibits the proliferation, migration, and invasion and promotes apoptosis of gastric cancer cells by targeting LASP1. Tumour Biol. 37:15241–15252. 2016. View Article : Google Scholar : PubMed/NCBI
14	Li H, Zhang H, Lu G, Li Q, Gu J, Song Y, Gao S and Ding Y: Mechanism analysis of colorectal cancer according to the microRNA expression profile. Oncol Lett. 12:2329–2336. 2016.PubMed/NCBI
15	Peng G, Liao Y and Shen C: miRNA-429 inhibits astrocytoma proliferation and invasion by targeting BMI1. Pathol Oncol Res. 23:369–376. 2017. View Article : Google Scholar : PubMed/NCBI
16	Wu D, Niu X, Pan H, Zhou Y, Qu P and Zhou J: MicroRNA-335 is downregulated in bladder cancer and inhibits cell growth, migration and invasion via targeting ROCK1. Mol Med Rep. 13:4379–4385. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang L, Huang D, Tan C, Xu Q, Zha R, et al: microRNA-202-3p inhibits cell proliferation by targeting ADP-ribosylation factor-like 5A in human colorectal carcinoma. Clin Cancer Res. 20:1146–1157. 2014. View Article : Google Scholar : PubMed/NCBI
18	Josson S, Gururajan M, Hu P, Shao C, Chu GY, Zhau HE, Liu C, Lao K, Lu CL, Lu YT, et al: miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res. 20:4636–4646. 2014. View Article : Google Scholar : PubMed/NCBI
19	Fan MQ, Huang CB, Gu Y, Xiao Y, Sheng JX and Zhong L: Decrease expression of microRNA-20a promotes cancer cell proliferation and predicts poor survival of hepatocellular carcinoma. J Exp Clin Cancer Res. 32:212013. View Article : Google Scholar : PubMed/NCBI
20	Du C, Weng X, Hu W, Lv Z, Xiao H, Ding C, Gyabaah OA, Xie H, Zhou L, Wu J and Zheng S: Hypoxia-inducible MiR-182 promotes angiogenesis by targeting RASA1 in hepatocellular carcinoma. J Exp Clin Cancer Res. 34:672015. View Article : Google Scholar : PubMed/NCBI
21	Chuang KH, Whitney-Miller CL, Chu CY, Zhou Z, Dokus MK, Schmit S and Barry CT: MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. Hepatology. 62:466–480. 2015. View Article : Google Scholar : PubMed/NCBI
22	Liang Z, Ahn J, Guo D, Votaw JR and Shim H: MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res. 30:1008–1016. 2013. View Article : Google Scholar : PubMed/NCBI
23	Liang Z, Bian X and Shim H: Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res Treat. 146:535–542. 2014. View Article : Google Scholar : PubMed/NCBI
24	Liu L, Lian J, Zhang H, Tian H, Liang M, Yin M and Sun F: MicroRNA-302a sensitizes testicular embryonal carcinoma cells to cisplatin-induced cell death. J Cell Physiol. 228:2294–2304. 2013. View Article : Google Scholar : PubMed/NCBI
25	Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
26	Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi S: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 27:854–861. 1997. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Mao B and Wang G: MicroRNAs involved with hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820. 2015. View Article : Google Scholar : PubMed/NCBI
29	Giordano S and Columbano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
30	Jin H, Yu M, Lin Y, Hou B, Wu Z, Li Z and Sun J: MiR-502-3P suppresses cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting SET. Onco Targets Ther. 9:3281–3289. 2016.PubMed/NCBI
31	Guo T, Yu W, Lv S, Zhang C and Tian Y: MiR-302a inhibits the tumorigenicity of ovarian cancer cells by suppression of SDC1. Int J Clin Exp Pathol. 8:4869–4880. 2015.PubMed/NCBI
32	Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ, Zhang HL, Zhu Y, Dai B, Shi GH and Ye DW: MicroRNA-302a suppresses tumor cell proliferation by inhibiting AKT in prostate cancer. PLoS One. 10:e01244102015. View Article : Google Scholar : PubMed/NCBI
33	Wei ZJ, Tao ML, Zhang W, Han GD, Zhu ZC, Miao ZG, Li JY and Qiao ZB: Up-regulation of microRNA-302a inhibited the proliferation and invasion of colorectal cancer cells by regulation of the MAPK and PI3K/Akt signaling pathways. Int J Clin Exp Pathol. 8:4481–4491. 2015.PubMed/NCBI
34	Fan L, Wu Q, Xing X, Wei Y and Shao Z: MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Shanghai). 44:407–414. 2012. View Article : Google Scholar : PubMed/NCBI
35	Ji YN, Wang Q, Li Y and Wang Z: Prognostic value of vascular endothelial growth factor A expression in gastric cancer: A meta-analysis. Tumour Biol. 35:2787–2793. 2014. View Article : Google Scholar : PubMed/NCBI
36	Huang YJ, Qi WX, He AN, Sun YJ, Shen Z and Yao Y: Prognostic value of tissue vascular endothelial growth factor expression in bladder cancer: A meta-analysis. Asian Pac J Cancer Prev. 14:645–649. 2013. View Article : Google Scholar : PubMed/NCBI
37	Youssef NS and Said AM: Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: Possible targets of new therapies. Int J Clin Exp Pathol. 7:5725–5737. 2014.PubMed/NCBI
38	Wen L, Wang R, Lu X and You C: Expression and clinical significance of vascular endothelial growth factor and fms-related tyrosine kinase 1 in colorectal cancer. Oncol Lett. 9:2414–2418. 2015.PubMed/NCBI
39	Zhuang Y and Wei M: Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: A meta-analysis. Tumour Biol. 35:1745–1749. 2014. View Article : Google Scholar : PubMed/NCBI
40	Liu Y, Zheng Q, Wu H, Guo X, Li J and Hao S: Rapamycin increases pCREB, Bcl-2, and VEGF-A through ERK under normoxia. Acta Biochim Biophys Sin (Shanghai). 45:259–267. 2013. View Article : Google Scholar : PubMed/NCBI
41	Wiszniak S, Mackenzie FE, Anderson P, Kabbara S, Ruhrberg C and Schwarz Q: Neural crest cell-derived VEGF promotes embryonic jaw extension. Proc Natl Acad Sci USA. 112:6086–6091. 2015; View Article : Google Scholar : PubMed/NCBI
42	Wu YY, Chen L, Wang GL, Zhang YX, Zhou JM, He S, Qin J and Zhu YY: Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF. J Mol Histol. 44:433–445. 2013. View Article : Google Scholar : PubMed/NCBI